Jill Roberts Center for Inflammatory Bowel Disease

Publications

Found 41 results
[ Author(Desc)] Title Type Year
Filters: Keyword is Female  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Agrawal M, Cohen-Mekelburg S, Kayal M, Axelrad J, Galati J, Tricomi B, Kamal K, Faye AS, Abrudescu P, Scherl E et al..  2019.  Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factors.. Aliment Pharmacol Ther. 49(5):564-571.
B
Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, Martel M, Seidman E, Afif W.  2017.  Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.. Clin Gastroenterol Hepatol. 15(9):1427-1434.e2.
Battat R, Kopylov U, Byer J, Sewitch MJ, Rahme E, Nedjar H, Zelikovic E, Dionne S, Bessissow T, Afif W et al..  2017.  Vitamin B12 deficiency in inflammatory bowel disease: a prospective observational pilot study.. Eur J Gastroenterol Hepatol. 29(12):1361-1367.
C
Castellanos JG, Woo V, Viladomiu M, Putzel G, Lima S, Diehl GE, Marderstein AR, Gandara J, Perez AR, Withers DR et al..  2018.  Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis.. Immunity. 49(6):1077-1089.e5.
Cohen-Mekelburg S, Gold S, Schneider Y, Dennis M, Oromendia C, Yeo H, Michelassi F, Scherl E, Steinlauf A.  2019.  Delays in Initiating Post-operative Prophylactic Biologic Therapy Are Common Among Crohn's Disease Patients.. Dig Dis Sci. 64(1):196-203.
Cohen-Mekelburg S, Tafesh Z, Coburn E, Weg R, Malik N, Webb C, Hammad H, Scherl E, Bosworth BP.  2018.  Testing and Treating Small Intestinal Bacterial Overgrowth Reduces Symptoms in Patients with Inflammatory Bowel Disease.. Dig Dis Sci. 63(9):2439-2444.
Cohen-Mekelburg S, Rosenblatt R, Gold S, Burakoff R, Waljee AK, Saini S, Schackman BR, Scherl E, Crawford C.  2018.  The Impact of Opioid Epidemic Trends on Hospitalised Inflammatory Bowel Disease Patients.. J Crohns Colitis. 12(9):1030-1035.
Cohen-Mekelburg S, Rosenblatt R, Gold S, Shen N, Fortune B, Waljee AK, Saini S, Scherl E, Burakoff R, Unruh M.  2019.  Fragmented Care is Prevalent Among Inflammatory Bowel Disease Readmissions and is Associated With Worse Outcomes.. Am J Gastroenterol. 114(2):276-290.
Cohen-Mekelburg S, Schneider Y, Gold S, Ghosh G, Rosenblatt R, Hajifathalian K, Scherl E, Schnoll-Sussman F, Katz P, Steinlauf A.  2019.  Risk of Early Colorectal Cancers Needs to Be Considered in Inflammatory Bowel Disease Care.. Dig Dis Sci. 64(8):2273-2279.
D
Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD.  2015.  Ulcerative Colitis Care Pathway.. Gastroenterology. 149(1):238-45.
DeFilippis EM, Barfield E, Leifer D, Steinlauf A, Bosworth BP, Scherl EJ, Sockolow R.  2015.  Cerebral venous thrombosis in inflammatory bowel disease.. J Dig Dis. 16(2):104-8.
Dogan B, Scherl E, Bosworth B, Yantiss R, Altier C, McDonough PL, Jiang Z-D, Dupont HL, Garneau P, Harel J et al..  2013.  Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease.. Inflamm Bowel Dis. 19(1):141-50.
Dogan B, Belcher-Timme HFacey, Dogan EI, Jiang Z-D, Dupont HL, Snyder N, Yang S, Chandler B, Scherl EJ, Simpson KW.  2018.  Evaluation of Escherichia coli pathotypes associated with irritable bowel syndrome.. FEMS Microbiol Lett. 365(22)
Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P et al..  2018.  Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.. Gastroenterology. 155(3):687-695.e10.
F
Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS et al..  2019.  Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.. Clin Gastroenterol Hepatol. 17(12):2497-2505.e1.
G
Ghosh G, Jacob V, Wan D.  2018.  Plasmablastic Lymphoma in a Patient With Crohn's Disease After Extensive Immunosuppressive Therapy.. Clin Gastroenterol Hepatol. 16(4):e41-e42.
J
Jacob V, Crawford C, Cohen-Mekelburg S, Viladomiu M, Putzel GG, Schneider Y, Chabouni F, OʼNeil S, Bosworth B, Woo V et al..  2017.  Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis.. Inflamm Bowel Dis. 23(6):903-911.
K
Koczka CPhilip, Abramowitz M, Goodman AJ.  2012.  The study of bone demineralization and its risk factors in an Afro-Caribbean subset of patients with inflammatory bowel disease.. Eur J Gastroenterol Hepatol. 24(7):759-61.
Kumar A, Kim M, Lukin DJ.  2018.  Helicobacter pylori is associated with increased risk of serrated colonic polyps: Analysis of serrated polyp risk factors.. Indian J Gastroenterol. 37(3):235-242.
L
Longman RS, Remotti H, Green PH.  2011.  Esophagitis dissecans superficialis.. Gastrointest Endosc. 74(2):403-4.
Longman RS, Talal AH, Jacobson IM, Albert ML, Rice CM.  2004.  Presence of functional dendritic cells in patients chronically infected with hepatitis C virus.. Blood. 103(3):1026-9.
Longman RS, Talal AH, Jacobson IM, Rice CM, Albert ML.  2005.  Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C.. J Infect Dis. 192(3):497-503.
Lukin DJ, Lawlor G, Hudesman DP, Durbin L, Axelrad JE, Passi M, Cavaliere K, Coburn E, Loftus M, Jen H et al..  2019.  Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile.. Inflamm Bowel Dis. 25(4):775-781.
Lukin DJ, Kumar A, Hajifathalian K, Sharaiha RZ, Scherl EJ, Longman RS.  2020.  Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease.. Gastroenterology. 159(4):1541-1544.e2.
M
Marion JF, Waye JD, Present DH, Israel Y, Bodian C, Harpaz N, Chapman M, Itzkowitz S, Steinlauf AF, Abreu MT et al..  2008.  Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial.. Am J Gastroenterol. 103(9):2342-9.